Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in RRMM

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.06.19
Views: 305

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

Dr Shaji Kumar presents results at the 2019 European Hematology Association (EHA) Annual Meeting from a study looking at the addition of venetoclax to bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

The trial randomised patients between venetoclax or placebo with bortezomib and dexamethasone and although patients receiving venetoclax saw an improved response and progression-free survival, there was an increase in treatment-emergent deaths.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation